Compare · FRMM vs NVS

FRMM vs NVS

Side-by-side comparison of Forum Markets Incorporated (FRMM) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.

Summary

  • FRMM operates in Finance, while NVS operates in Health Care - the two are in different parts of the market.
  • NVS is the larger of the two at $305.69B, about 9542.8x FRMM ($32.0M).
  • Over the past year, FRMM is down 81.6% and NVS is up 21.8% - NVS leads by 103.4 points.
  • FRMM has been more active in the news (6 items in the past 4 weeks vs 5 for NVS).
  • NVS has more recent analyst coverage (25 ratings vs 1 for FRMM).
PerformanceFRMM-81.57%NVS+21.79%
2025-11-17+0.00%2026-11-16
MetricFRMMNVS
Company
Forum Markets Incorporated
Novartis AG
Price
-
-
Market cap
$32.0M
$305.69B
1M return
-36.70%
+6.36%
1Y return
-81.57%
+21.79%
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
2017
News (4w)
6
5
Recent ratings
1
25
NVS

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Latest FRMM

Latest NVS